Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma

Highly Entrenched Rituxan Could Prove Tough To Dislodge

 
• By Alaric DeArment
  
Cancer-cells-pink-color_1200x675
Roche presented data at ASCO on its two CD20xCD3-targeting bispecific antibodies • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

More from Conferences